Brain computer interfaces are rapidly moving from experimental neuroscience projects toward real world medical and technological applications. As researchers and technology companies race to improve how humans interact with machines through neural signals, one of the biggest challenges remains collecting high quality brain data safely and at scale. Many existing brain interface systems rely on rigid implants that penetrate brain tissue, creating limitations around long term safety, scalability, and patient adoption. Switzerland based neurotechnology company Neurosoft Bioelectronics is developing a different approach using soft and minimally invasive neural interfaces, and investors are backing the company with fresh funding.
Neurosoft Bioelectronics has raised $7.5 million in an oversubscribed seed funding round led by Skybound Venture Capital, with participation from Protocol Labs, IAG Capital Partners, and Connecticut Innovations, among other investors.
The latest financing brings the company’s total funding to more than $20 million.
Building a Less Invasive Brain Interface
Headquartered in Switzerland with operations in New York, Neurosoft Bioelectronics is developing a platform designed to access the full cortex without penetrating brain tissue directly.
The company’s core technology is based on proprietary soft and stretchable electrodes that are significantly more flexible and compliant than traditional neural interfaces. Unlike rigid implants, these electrodes are designed to conform more naturally to brain surfaces while supporting broader cortical coverage through minimally invasive procedures.
The startup believes this approach could help improve both the safety and scalability of future brain computer interface systems.
Creating a Neural Data Platform
Beyond hardware development, Neurosoft says its long term vision is to build a large scale neural data platform capable of supporting foundation models of the human cortex.
The company believes the neural data collected through its implantable systems could eventually help improve both invasive and non invasive brain computer interfaces by enabling more advanced machine learning models trained on high quality cortical data.
According to Nicolas Vachicouras, the company’s soft electrode technology combined with its regulatory strategy allows Neurosoft to collect neural data at a scale and quality difficult to achieve safely using many existing alternatives.
Vachicouras said this data will form the basis for improved clinical outcomes and future cortical foundation models capable of shaping the next generation of neural interfaces.
Advancing Human Clinical Trials
To date, Neurosoft Bioelectronics has tested its technology in 10 patients across two ongoing clinical trials at UTHealth Houston and UMC Utrecht.
One of the ongoing studies includes a 64 channel soft brain interface system designed to support epilepsy surgery guidance.
The company says its broader technology portfolio now includes more than 25 patents and over 25 peer reviewed scientific publications focused on neural engineering and brain interface systems.
Growing Interest in Brain Computer Interfaces
Brain computer interfaces are attracting increasing attention from both investors and technology companies as advances in neuroscience, materials science, artificial intelligence, and bioelectronics accelerate the field’s development.
Applications for BCIs are expanding beyond medical use cases into broader areas such as communication technologies, neuroprosthetics, cognitive monitoring, and eventually human machine interaction systems.
However, one of the industry’s biggest technical challenges remains balancing neural signal quality with safety and long term usability. Companies capable of developing less invasive systems while still generating high quality neural data are becoming increasingly important within the sector.
Preparing for Commercialisation
With the new funding, Neurosoft Bioelectronics plans to advance several major clinical and commercial milestones.
The company aims to demonstrate minimally invasive deployment of its systems in human patients while progressing toward commercialisation of its first brain interface product in the United States.
As neural interface technologies continue evolving, Neurosoft Bioelectronics is positioning itself within a growing generation of neurotechnology companies seeking to make brain computer interfaces safer, more scalable, and capable of supporting increasingly advanced AI driven neuroscience applications.
